Take a look at our library of publications and presentations that cover the topic of our technology and its areas of application in more detail.
Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.
Casado P, Wilkes EH, Miraki-Moud F, Hadi MM, Rio-Machin A, Rajeeve V, Pike R, Iqbal S, Marfa S, Lea N, Best S, Gribben J, Fitzgibbon J, Cutillas PR. 2018, Leukemia, pp. 1818-1822
Kinase activity ranking using phosphoproteomics data (KARP) quantifies the contribution of protein kinases to the regulation of cell viability.
Wilkes EH, Casado P, Rajeeve V, Cutillas PR. 2017, Molecular & Cellular Proteomics, pp. 1694-1704
Wilkes EH, Terfve C, Gribben JG, Saez-Rodriguez J, Cutillas PR. 2015, PNAS (Proceedings of the National Academy of Sciences of the United States of America), pp.7719-7724
Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.
Casado P, Rodriguez-Prados JC, Cosulich SC, Guichard S, Vanhaesebroeck B, Joel S, Cutillas PR. 2013, Science Signaling, pp. rs6
Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.
Alcolea MP, Casado P, Rodríguez-Prados JC, Vanhaesebroeck B, Cutillas PR. 2012, Molecular & Cellular Poteomics, pp 453-466
A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments.
Casado P, Cutillas PR. 2011, Molecular & Cellular Proteomics
Cutillas PR, Vanhaesebroeck B. 2007, Molecular & Cellular Proteomics, pp. 1560-73
Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line.
Cutillas PR, Geering B, Waterfield MD, Vanhaesebroeck B. 2005, Molecular & Cellular Proteomics, pp. 1038-51
“Our technology can look at over 10,000 proteins in one simple experiment and tell researchers exactly which proteins are activated and deactivated. This is hugely important and relevant for personalised medicine“
Jane Theaker, Kinomica CEO